Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06208943 · ClinicalTrials.gov registry record

Neural and Cognitive Consequences of COVID-19 Survival

A clinical trial of COVID-19 and Fatigue, sponsored by San Francisco Veterans Affairs Medical Center.

Recruiting
Registry status
150
Enrollment target
1
Study location

NCT06208943: Recruiting study of COVID-19 and Fatigue, sponsored by San Francisco Veterans Affairs Medical Center.

NCT06208943 is a study of COVID-19 and Fatigue that is actively recruiting participants, run by San Francisco Veterans Affairs Medical Center. The registered enrollment target is 150 participants, below the 38,464-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06208943, a study of COVID-19 and Fatigue, is actively recruiting participants, sponsored by San Francisco Veterans Affairs Medical Center.

RECRUITING
Registry status
150 participants
Enrollment target
1
Study location

Study Summary

The novel coronavirus SARS-CoV-2 infection, COVID, continues to rage throughout the world with 115,000,000 confirmed cases and over 2,500,000 deaths (as of Mar 3, 2021). This translates to millions of people surviving COVID19 infection. While the lungs are ground zero, COVID tears through organ systems from brain to blood vessels. We are now beginning to see people recover but complain of ongoing problems, including lingering cognitive problems, depression, and anxiety. We have brought together 2 laboratories with complementary techniques including psychological testing and neuroimaging methods togethers with markers in the blood that may signal damage in the brain. A close look at these problems is timely and imperative if we are to understand the pathophysiology of 'COVID brain' and prepare for downstream problems.

Interventions

  • OTHER cross-sectional MRI and EEG assessments (NO INTERVENTION)

Study Locations (1)

California

  • San Francisco Heathcare System - San Francisco

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2021-10-01
Est. Completion 2025-09-30

What NCT06208943 shows while recruiting

NCT06208943 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 38,464-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower).

The record links to 7 conditions, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which cross-sectional MRI and EEG assessments (NO INTERVENTION) is the first listed.

NCT06208943 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT06208943 about?

NCT06208943 is a clinical study titled "Neural and Cognitive Consequences of COVID-19 Survival". The novel coronavirus SARS-CoV-2 infection, COVID, continues to rage throughout the world with 115,000,000 confirmed cases and over 2,500,000 deaths (as of Mar 3, 2021). This translates to millions of people surviving COVID19 infection. While the lungs are ground zero, COVID tears through organ syst...

What is the current status of trial NCT06208943?

This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2021-10-01. Estimated completion is 2025-09-30.

What conditions does trial NCT06208943 study?

This clinical trial studies the following conditions: COVID-19, Fatigue, Brain Fog, COVID Long-Haul, COVID-19 Pandemic.

What interventions are being tested in trial NCT06208943?

The interventions under investigation include: cross-sectional MRI and EEG assessments (NO INTERVENTION) (OTHER).

Who is sponsoring clinical trial NCT06208943?

This trial is sponsored by San Francisco Veterans Affairs Medical Center, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06208943 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for COVID-19

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06208943's enrollment target sits among peer trials

150 173rd of 298 higher than 123 of 298 other COVID-19 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00412594 · 150 participants · Phase 2

    Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

  • NCT01484730 · 150 participants

    A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion

  • NCT01985919 · 150 participants

    Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples

  • NCT02016248 · 150 participants · NA

    SBRT Boost for Unfavorable Prostate Cancer'

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06208943, the US trial registry maintained by the National Library of Medicine. NCT06208943 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.